PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.

Abstract Alternative pre-mRNA splicing is a crucial process that allows the generation of diversified RNA and protein products from a multi-exon gene. In tumor cells, this mechanism can facilitate cancer development and progression through both creating oncogenic isoforms and reducing the expression of normal or controllable protein species. We recently demonstrated that an alternative cyclin D-binding myb-like transcription factor 1 (DMTF1) pre-mRNA splicing isoform, DMTF1β, is increasingly expressed in breast cancer and promotes mammary tumorigenesis in a transgenic mouse model. Aberrant pre-mRNA splicing is a typical event occurring for many cancer-related functional proteins. In this review, we introduce general aberrant pre-mRNA splicing in cancers and discuss its therapeutic application using our recent discovery of the oncogenic DMTF1 isoform as an example. We also summarize new insights in designing novel targeting strategies of cancer therapies based on the understanding of deregulated pre-mRNA splicing mechanisms.
PMID
Related Publications

Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma.

Re-splicing of mature mRNA in cancer cells promotes activation of distant weak alternative splice sites.

Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.

Misregulation of pre-mRNA alternative splicing in cancer.

Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors

Mayor MeshTerms
Keywords

DMTF1

alternative splicing

cancer therapy

tumorigenesis

Journal Title international journal of molecular sciences
Publication Year Start




PMID- 28257090
OWN - NLM
STAT- In-Process
DA  - 20170303
LR  - 20170303
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 18
IP  - 3
DP  - 2017 Mar 02
TI  - From General Aberrant Alternative Splicing in Cancers and Its Therapeutic
      Application to the Discovery of an Oncogenic DMTF1 Isoform.
LID - E191 [pii]
LID - 10.3390/ijms18030191 [doi]
AB  - Alternative pre-mRNA splicing is a crucial process that allows the generation of 
      diversified RNA and protein products from a multi-exon gene. In tumor cells, this
      mechanism can facilitate cancer development and progression through both creating
      oncogenic isoforms and reducing the expression of normal or controllable protein 
      species. We recently demonstrated that an alternative cyclin D-binding myb-like
      transcription factor 1 (DMTF1) pre-mRNA splicing isoform, DMTF1beta, is
      increasingly expressed in breast cancer and promotes mammary tumorigenesis in a
      transgenic mouse model. Aberrant pre-mRNA splicing is a typical event occurring
      for many cancer-related functional proteins. In this review, we introduce general
      aberrant pre-mRNA splicing in cancers and discuss its therapeutic application
      using our recent discovery of the oncogenic DMTF1 isoform as an example. We also 
      summarize new insights in designing novel targeting strategies of cancer
      therapies based on the understanding of deregulated pre-mRNA splicing mechanisms.
FAU - Tian, Na
AU  - Tian N
AD  - College of Life Science, Northeast Forestry University, Harbin 150040, China.
      [email protected]
FAU - Li, Jialiang
AU  - Li J
AD  - College of Life Science, Northeast Forestry University, Harbin 150040, China.
      [email protected]
FAU - Shi, Jinming
AU  - Shi J
AD  - College of Life Science, Northeast Forestry University, Harbin 150040, China.
      [email protected]
FAU - Sui, Guangchao
AU  - Sui G
AD  - College of Life Science, Northeast Forestry University, Harbin 150040, China.
      [email protected]
AD  - Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest
      University School of Medicine, Winston-Salem, NC 27157, USA. [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170302
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
OTO - NOTNLM
OT  - DMTF1
OT  - alternative splicing
OT  - cancer therapy
OT  - tumorigenesis
EDAT- 2017/03/04 06:00
MHDA- 2017/03/04 06:00
CRDT- 2017/03/04 06:00
PHST- 2016/11/23 [received]
PHST- 2017/01/03 [revised]
PHST- 2017/01/10 [accepted]
AID - ijms18030191 [pii]
AID - 10.3390/ijms18030191 [doi]
PST - epublish
SO  - Int J Mol Sci. 2017 Mar 2;18(3). pii: E191. doi: 10.3390/ijms18030191.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>